SAN FRANCISCONovo Nordisk may have already submitted its approval application for its oral GLP-1 drug semaglutide, but the deluge of positive data hasnt stopped.
Tuesday at the American Diabetes Association annual meeting, the Danish drugmaker rolled out car…
Read More